Cell-stage dependence of mutagen-induced sister-chromatid exchanges in human lymphocyte cultures.
The induction of sister-chromatid exchanges (SCEs) was studied in phytohemagglutinin (PHA)-stimulated human lymphocytes exposed for 1 h to mitomycin C (MMC, 3 X 10(-6) M), ethyl methanesulphonate (EMS, 2 X 10(-2) M), or 4-nitroquinoline-1-oxide (4NQO, 3 X 10(-5) M) at various cell-cycle stages of 72-h cultures. The doses of the chemical were chosen to give about 20 SCEs per cell when treated at Go. The SCE frequency increased almost linearly with MMC or EMS treatments at later times after PHA stimulation, peaking with those at 36 h (at around the first G1/S boundary in the 2 consecutive cell cycles, which was revealed by concomitant experiments), and then decreased with subsequent treatment times. Cell-cycle kinetics and the cell stages at which the cells were treated were measured by autoradiography and sister-chromatid differential staining. The data show that MMC and EMS produce larger numbers of SCEs when treated at stages closer to the beginning of S, and that the most efficient time of treatment is the G1/S boundary in the first cell cycle of the two consecutive cycles before sampling. Pulse treatment with EMS caused about 3 times larger inductions of SCEs when done at late G1/early S(G1/S boundary) in the first cell cycle compared to that at G0/early G1, whereas identical exposure to MMC at the first G1/S boundary produced only 1.5 times larger numbers of SCEs than that at G0/early G1. EMS and MMC both, however, induced 30-40% larger numbers of SCEs when treated at the G1/S boundary in the first cell cycle than when treated at the second cell cycle before sampling. On the contrary, treatment with 4NQO led to the induction of about the same numbers of SCEs even when treated at different cell-cycle stages before the second G1/S boundary. The SCE frequency in 4NQO-treated cells then decreased with subsequent treatment times.
D015112:4-Nitroquinoline-1-oxide / Q000009:adverse effects; D000328:Adult; D002453:Cell Cycle; D002478:Cells, Cultured; D005020:Ethyl Methanesulfonate / Q000009:adverse effects; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000166:cytology / Q000648:ultrastructure*; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects; D009153:Mutagens; D012854:Sister Chromatid Exchange / Q000187:drug effects*
D008937:Mitomycins; D009153:Mutagens; D016685:Mitomycin; D015112:4-Nitroquinoline-1-oxide; D005020:Ethyl Methanesulfonate